Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cybin ( (TSE:CYBN) ) has provided an announcement.
Cybin announced a leadership change with Doug Drysdale stepping down as CEO and Eric So, the Co-Founder and President, taking over as Interim CEO. This transition is aimed at maintaining continuity and advancing the clinical pipeline, particularly focusing on the approval of CYB003 and CYB004. The Board has initiated a search for a new CEO to lead the company through commercialization and continue its mission to transform mental healthcare.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$39.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin is a late-stage breakthrough neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is working on novel drugs like CYB003 and CYB004 for mental health conditions, with operations in Canada, the United States, the United Kingdom, and Ireland.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
Find detailed analytics on CYBN stock on TipRanks’ Stock Analysis page.